Expert Interviews

Nicholas Brownstone, MD, showcased multidisciplinary collaboration and educational podcast initiatives aimed at supporting both dermatology trainees and patients.

Harrison Nguyen, MD, MBA, MPH, FAAD, shares early career billing, coding, and mentorship tips for dermatologists at Winter Clinical Miami 2026.

At Winter Clinical Miami 2026, Linda Stein Gold, MD, FAAD, shared acne and rosacea tips and previewed psoriasis oral advances like icotrokinra.

Mark Lebwohl, MD, shares his Winter Clinical Miami 2026 highlights, including oral psoriasis peptides, atopic dermatitis advances, GLP-1 combos, and more.

Systemic mastocytosis often hides behind common symptoms; learn why early, team-based diagnosis and tailored staging prevent delays and risks.

In a Derm Dispatch discussion, Renata Block, DMSc, MMS, PA-C, and Lauren Madigan, MD, review practical strategies for diagnosing and managing cutaneous mastocytosis across age groups.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Shanna Miranti, MPAS, PA-C, discuss how “taking off the clinician mask” can strengthen trust and improve shared decision-making in the exam room.

In this first episode, Dr. Hadar Lev-Tov and Dr. Martina Porter convene for a clinical journal club to discuss the emerging landscape of Hidradenitis Suppurativa (HS) treatment.

Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.

In an interview with Dermatology Times, Michael O’Donoghue, MD, describes how a standardized protocol supports efficient and consistent delivery of photodynamic therapy.

BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.

Experts discuss how seborrheic dermatitis can be distinguished from atopic dermatitis and psoriasis through clinical features and underlying immune patterns, highlighting the role of Th17/Th22-driven inflammation and barrier dysfunction in guiding more precise, targeted treatment strategies.

Experts discuss how seborrheic dermatitis arises from a multifactorial interplay of immune dysregulation, Malassezia yeast colonization, epidermal barrier impairment, and sebaceous gland activity, shaping its chronic nature and informing targeted treatment approaches.

Experts discuss the complexities of treating psoriatic arthritis, emphasizing the need for a multifaceted approach and potential medication switches.

Explore the complexities of managing psoriatic arthritis in dermatology, focusing on effective treatment strategies and patient care insights.

Patient advocate Suki Tipp details her progression from misattributed cutaneous findings and fragmented specialty care to life-threatening anaphylaxis and eventual disease control with targeted therapy.

Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.

In a conversation with Dermatology Times, Del Rosso highlighted the growing range of systemic and procedural therapies available to clinicians.

Systemic mastocytosis often hides behind common symptoms; learn why early, team-based diagnosis and tailored staging prevent delays and risks.

Michael O’Donoghue, MD, outlines how delegating PDT workflows to trained medical assistants can preserve physician time while maintaining treatment quality.

Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.

BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.

At the 2026 South Beach Symposium, Joel Claveau, MD, emphasized that accurate early diagnosis and proper staging are the cornerstones of effective melanoma management.

Todd Schlesinger, MD, highlights data supporting red light–activated PDT with 10% ALA gel for superficial basal cell carcinoma, discussing structured treatment protocols and manageable tolerability.

Misha Rosenbach, MD, discussed the burden of cutaneous sarcoidosis (CS) and how emerging therapies like brepocitinib could fill this clinical need.

Healthcare professionals discuss the complexities of treating psoriasis, emphasizing patient communication and individualized care for optimal outcomes.

Explore the complexities of managing psoriasis in a typical patient, focusing on treatment challenges and psychosocial impacts.

Highlighting conditions like lichen planus, which has no FDA-approved treatments, Lio underscores why clinicians must be comfortable prescribing beyond the label.

As we celebrate Valentine's Day, Mona Shahriari, MD, FAAD; Neal Bhatia, MD; Peter Lio, MD; Lisa Swanson, MD; Lawrence Schachner, MD; Julie Karen, MD; and Glynis Ablon, MD, FAAD, share why they love dermatology.

Learn how skin clues reveal systemic mastocytosis early, from subtypes to KIT D816V mutations that guide targeted treatment.